Lumicell’s single-cell imaging technology for eliminating residual cancer cells during tumor resection is one step closer to the clinic. Following fast track designations for the imaging agent/device pair and the recent conclusion of a pivotal trial in breast cancer patients, the company has filed a New Drug Application on its signature platform.
The technology’s early development was supported by the Koch Institute Frontier Research Program via the Curt and Kathy Marble Cancer Research Fund.